



## Perspectives on Kaposi's Sarcoma

Guest Editor:

**Prof. Jean-Philippe Spano**

Service d'Oncologie Médicale,  
Hôpital Pitié Salpêtrière,  
Sorbonne Université, AP-HP,  
Paris, France

Deadline for manuscript  
submissions:

**closed (30 November 2021)**

### Message from the Guest Editor

Kaposi's sarcoma (KS) remains a tumor that in most cases is associated with human herpes virus 8 (HHV8 or K-HSV) infection. KS can occur in immunocompetent subjects (the endemic part) and in immunosuppressed patients (HIV or post-transplant for instance). In Patients Living With HIV (PLWHIV), the incidence has dramatically decreased since the advent of HAART and, also thanks to the better control of HIV replication. Some case reports and recent series have mentioned that cutaneous and/or visceral KS could occur in PLWHIV on antiretroviral therapy, with suppressed HIV viremia and high CD4T cell counts without any efficiency of conventional therapies. The hope now and in the near future seems to be based upon new drugs (targeted therapies, or new immunotherapeutic agents) that improve KS patients' outcomes.

This Special Issue will focus on current data concerning the pathogenesis of KS, particularly driven by infection of endothelial cells with HHV8, and the potential impact of new therapeutic approaches beyond the conventional chemotherapy and interferon use.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)